Novel amino acid derivatives

Abstract: Compounds of the formula: (wherein R¹ is hydrogen or alkyl; R² is an optionally substituted carbocyclic or heterocyclic ring; Z is hydrogen or a group -COR⁹, (R⁹ is alkyl or phenyl) in which R¹⁰ is hydrogen, halogen, trihalomethyl, alkyl or alkoxy, R¹¹ and R¹² are each hydrogen, alkyl or phenyl substituted by R¹⁰, or R¹¹ and R¹² together represent alkylene and p is 1 or 2; q is 1 to 4; A is phenyl or cycloalkyl optionally substituted by halogen, trihalomethyl, alkyl or alkoxy; and m is zero and n is 1 to 4 or n is zero and m is 1 to 4; and non-toxic salts thereof, have an inhibitory effect on enkephalinase and are useful as analgesic, antianxiety and anticonvulsant agents.

Description: This invention relates to novel amino acid derivatives having an inhibitory activity on enkephalinase, to processes for their preparation, pharmaceutical compositions containing them and to their use. "Enkephalin" is a general term referring to compounds of the formula: Try-Gly-Gly-Phe-A (wherein A represents Met (in Met⁵-enkephalin) or Leu (in Leu⁵-enkephalin)). These two pentapeptides bind to opioid receptors and thereby produce an analgic effect. They are neurotransmitters (see Nature, 258 , 577 (1975)). Enkephalinase, discovered by Malfroy et al, is an enzyme which cleaves Met-enkephalin or Leu-enkephalin at the Gly³-Phe⁴ bond (see Nature, 276 , 523 (1978)). It plays an important role in the termination of the analgesic effect which enkephalin has. It is considered that the inhibition of enkephalinase slows down the deactivation of enkephalin and that the analgesic effect is maintained. On this basis, there has recently been active research and development on enkephalinase inhibitors. For example, in European Patent Publication No. 38758, the compounds of the general formula: [wherein Xa-Ya represents, inter alia, a mercapto group, na represents zero or one, Aa-Ba represents, inter alia, a CONH group, R 1a represents, inter alia, a hydrogen atom, or optionally substituted alkyl group or an optionally substituted phenyl group, R 2a represents a hydrogen atom, an alkyl group, a phenyl group, an optionally substituted benzyl group, a hydroxyalkyl group, an optionally substituted alkoxyalkyl group, a phenoxyalkyl group or an optionally substituted mercaptoalkyl group, R 3a represents a group of the formula: OR 4a , NHR 4a or N(R 4a )₂ in which R 4a represents, inter alia, an optionally substituted phenyl)are proposed. In particular thiorphan having the formula: is noted (see Nature, 288 , 286 (1980)). Thereafter, compounds wherein the glycine moiety in thiorphan is replaced by various substituents, have been proposed. For example, in European Patent Publication No. 136883 (and Japanese Patent Kokai No. 60-136554), the compounds of the general formula: (wherein R 1b represents a hydrogen atom or R 2b represents, inter alia, a group of the formula: R 3b represents a hydrogen atom, an alkyl group, a group of the formula: or -(CH₂) pb -cycloalkyl, R 4b represents a hydroxy group, an alkoxy group a group of the formula: -O-(CH₂) pb+1 -OH, and nb represents an integer of 1 to 15) are proposed. In South African Patent Publication No. 840670, the compounds of the general formula: (wherein R 1c represents a hydrogen atom, an acyl group or an aroyl group, R 2c represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or aralkyl group, R 3c represents a hydrogen atom, an alkyl group, a carboxy group, a carboxyamido group, a substituted alkyl group, a substituted aryl group, a thiol group, an alkylthio group or a heteroaryl group, R 4c represents a group of the formula: nc represents an integer of 1 to 3, and R 5c represents a hydroxy group, an alkoxy group, an aryloxy group, an aralkyloxy groin, an NH₂ group, or a group of the formula: NR 6c R 7c or are proposed. In the U.S. Patent No. 4401677, the compounds of the general formula: (wherein R 1d represents an alkyl group, a benzyl group or a phenethyl group, R 2d represents an alkyl group or a group of the formula: -(CH₂) nd -NH₂, -(CH₂) nd -SH, -(CH₂) nd -S- alkyl, and nd represents an integer of 1 to 4) are proposed. Further, in European Patent Publication No. 254032, the compounds of the general formula: (wherein R 1ae represents a phenyl group substituted by, inter alia, alkyl, alkoxy or cycloalkyl. R 2e represents, inter alia, a group of the formula: R 13e CONH(CH₂) qe -, R 13e NHCO(CH₂) qe -, R 6e OCO(CH₂) qe - R 3e represents, inter alia, a group of the formula: OR 7e , - NR 7e R 8e , R 13e represents, inter alia, a group of the formula: Y 1e -C₆H₄-, R 6e , R 7e and R 8e represent, independently, inter alia, a hydrogen atom, an alkyl group or an arylalkyl group, ne represents zero or an integer 1 or 2, qe represents an integer 1 to 4, Qe represents a hydrogen atom or a group of the formula: R 10e CO-, R 10e represents, inter alia, an alkyl group or a group of the formula: Y 3e -C₆H₄-, Y 1e and Y 3e represent independently, inter alia, a hydrogen atom, an alkyl group, cycloalkyl group or an alkoxy group) are proposed. As a result of research and experimentation it has been found that derivatives wherein (1) a glycine moiety in thiorphan is replaced by an acidic α-amino acid (e.g. aspartic acid, glutamic acid etc.) and further (2) one carboxyl group of the said acidic amino acids is converted into an amido bond with various carbocyclic or heterocyclic amines, eg aromatic amines have an inhibitory effect on enkephalinase. Accordingly, the present invention relates to the amino acid derivatives of the general formula: (wherein R¹ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R² represents a carbocyclic or heterocyclic ring, unsubstituted or substituted by 1 to 3 substituents R³, R³ represents independently; (1) a halogen atom, (2) a trihalomethyl group, (3) a hydroxy group, (4) an alkyl group of 1 to 15 carbon atoms, (5) an alkoxy group of 1 to 4 carbon atoms, (6) an alkylthio, alkylsulfinyl or alkylsulfonyl group, of 1 to 4 carbon atoms, (7) a group of the formula: in which R⁴ represents a hydrogen atom, a halogen atom, a trihalomethyl group, a hydroxy group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms (8) a group of the formula: ―NR⁵R⁶ in which R⁵ and R⁶ independently represent a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (9) a group of the formula: ―CO―R⁷ in which R⁷ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R⁴ (in which R⁴ is as hereinbefore defined), (10) a group of the formula: ―COOR⁸ in which R⁸ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (11) a group of the formula: ―CONR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (12) a group of the formula: ―SO₂NR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (13) a cyano group, (14) a nitro group, or (15) a group of the formula: ―NHCO―R⁷, in which R⁷ is as hereinbefore defined, Z represents: (1) a hydrogen atom, (2) a group of the formula: ―COR⁹ in which R⁹ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, (3) a group of the formula: in which R¹⁰ is as hereinbefore defined, (4) a group of the formula: in which R¹¹ and R¹² independently represent a hydrogen atom, an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ is as hereinbefore defined, or R¹¹ and R¹² together represent an alkylene group of 4 or 5 carbon atoms and p is an integer of 1 or 2, (5) a group of the formula: in which the two R¹⁰ groups are independently as, hereinbefore defined, (6) a group of the formula: in which R¹⁰ is as hereinbefore defined and q is an integer of 1 to 4, (7) a group of the formula: in which R¹⁰ is as hereinbefore defined, A represents a phenyl group or cycloalkyl group of 4 to 7 carbon atoms, each of which is substituted by R¹³, in which R¹³ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, and m is an integer of 1 to 4), or a non-toxic salt thereof. There is no description of compounds of the general formula (I) in any of the prior art disclosing the general formulae (a) and (e) mentioned above. In the general formula (I), the alkyl groups of 1 to 4 carbon atoms, represented by R¹, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are methyl, ethyl, propyl and butyl groups, and isomers thereof. The alkoxy groups of 1 to 4 carbon atoms, represented by R³, R⁴, R¹⁰ and R¹³ are methoxy, ethoxy, propoxy and butoxy groups, and isomers thereof. The alkylthio groups of 1 to 4 carbon atoms, represented by R³ are methylthio, ethylthio, propylthio and butylthio groups, and isomers thereof; the alkylsulfinyl groups of 1 to 4 carbon atoms are methylsulfinyl, ethylsulfinyl, propylsulfinyl and butylsulfinyl groups, and isomers thereof; and the alkylsulfonyl groups of 1 to 4 carbon atoms are methylsulfonyl, ethylsulfonyl, propylsulfonyl and butylsulfonyl groups, and isomers thereof. The alkyl groups of 1 to 15 carbon atoms, represented by R³ are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and pentadecyl groups, and isomers thereof. The halogen atoms represented by R³, R⁴, R¹⁰ and R¹³ are fluorine, chlorine, bromine and iodine atoms, and the trihalomethyl groups represented by R³, R⁴, R¹⁰ and R¹³ are trifluoromethyl, trichloromethyl, tribromomethyl and triiodomethyl groups. The alkylene group of 4 or 5 carbon atoms, represented by R¹¹ and R¹² together, are tetramethylene or pentamethylene group. In the general formula (I), the carbocylic rings represented by R² are generally mono-, bi- or tri-cyclic aromatic carbocyclic rings containing not more than 15 carbon atoms, which may be partially or fully saturated. Examples of the rings mentioned above are benzene, naphthalene, indene, azulene, fluorene, phenanthrene, anthracene, acenaphthalene, biphenylene rings and partially or fully saturated rings thereof. More preferably, the carbocyclic ring is a mono-, bi- or tri-cyclic aromatic ring composed of benzene skeletons, i.e. benzene, naphthalene, phenanthrene and anthracene. In the general formula (I), the heterocyclic rings represented by R² are generally mono-, bi- or tri-aromatic heterocyclic rings containing not more than 15 carbon and hetero atoms; the rings may be partially or fully saturated. Examples of the rings mentioned above are furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, furazan, pyran, pyridine, pyridazine, pyrimidine, pyrazine, indole, isoindole, benzofuran, benzothiophene, indolizine, benzimidazole, benzthiazole, benzoxazole, chromene, quinoline, isoquinoline, quinolizine, purine, indazole, quinazoline, cinnoline, quinoxaline, phthaliazine, pteridine, benzodiazepine carbazole, acridine, phenanthridine, xanthene, phenazine and phenothiazine rings and partially or fully saturated rings thereof. More preferably, the hetorocyclic ring is mono- cyclic or bi-cyclic incorporating a benzene ring, and contains one or two nitrogen and/or sulfur atoms. Especially preferred rings represented by R² are benzene, naphthalene, furan, thiophene, pyridine, pyrimidine, pyrazine, benzimidazole, benzthiazole, benzoxazole and benzodiazepine rings and partially saturated rings thereof. In the general formula (I), the cycloalkyl groups of 4 to 7 carbon atoms, represented by A are cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups. A preferably represents a phenyl group or a cycloalkyl group of 4 to 7 carbon atoms, each of which is substituted by R¹³ (R¹³ being as hereinbefore defined). The compounds of general formula (I) may be converted into the corresponding salts by known methods. Non-toxic and water-soluble salts are preferable. Suitable salts include alkali metal salts (e.g. sodium or potassium), alkaline earth metal salts (e.g. calcium or magnesium), ammonium salts, salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine or N-methyl-D-glucamine). Non-toxic acid addition salts are also suitable when the compounds of general formula (I) comprise a basic group, for example when Z represents a nicotinoyl group. Suitable salts include the acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, phosphonic acid and nitric acid, and the salts with organic acids such as acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, benzoic acid, methansulphonic acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid, isethionic acid, glucuronic acid and gluconic acid. The compounds of general formula (I) can be named as derivatives of an amino acid. For example, the compound of the formula: can be called N-(3-mercapto-2-benzylpropionyl)-α-(4-chloroanilino) glutamic acid γ-sodium salt. Compounds of the invention in which the amino acid has the L-configuration are preferred. Throughout the specification including the claims, it is to be understood that the alkyl, alkoxy, alkylthio, alkylsulfinyl and alkylsulfonyl groups may be straight- or branched-chain. It is also to be understood that the invention includes all isomers (and mixtures thereof) arising from, for example, the presence of asymmetric carbons in general formula (I). According to a feature of the present invention, the compounds of the general formula (I) may be prepared by using a series of reactions depicted in Scheme A, B and C below, wherein R 1' represents an alkyl group of 1 to 4 carbon atoms, R¹⁴ represents a silyl group substituted by three substituents which are selected from an alkyl group of 1 to 4 carbon atoms and a phenyl group (e.g. a tert-butyldimethylsilyl or diphenyl-tert-butylsilyl group), Z¹ represents a group of the formula: -COR⁹ (in which R⁹ is as hereinbefore defined), Z² represents a group within the definition of Z as hereinbefore defined with the exception of hydrogen, t Bu represents a tert-butyl group, Bn represents a benzyl group, and m₁ is an integer of 2 to 4, and the other symbols are as hereinbefore defined. Each of the steps depicted in the said schemes, are well known to those skilled in the art. For example, Reaction 1 may be carried out by reacting an amine of the formula (II) with a carboxylic acid of the formula: (wherein the various symbols are as hereinbefore defined) to form an amido bond. The said reaction is known and can be carried out by various methods for example: (A) using a mixed acid anhydride, (B) using an acid halide, (C) using a condensing agent such as dicyclohexylcarbodiimide (DCC). Each of these methods can be carried out, for example, as follows: (A) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid of the general formula (VI) and an acid halide (e.g. pivaloyl chloride, tosyl chloride or mesyl chloride) or an acid derivative (e.g. ethyl chloroformate or isobutyl chloroformate) in the presence of a tertiary amine (e.g. pyridine, triethylamine or picoline) in an inert organic solvent (e.g. chloroform, methylene chloride, diethyl ether or THF) or without a solvent at a temperature of from 0°C to 40°C, and then by reacting the mixed acid anhydride obtained with an amine of the general formula (II) in an inert organic solvent (e.g. as hereinbefore described), at a temperature of from 0°C to 40°C, (B) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid of the general formula (VI) with an acid halide (e.g. thionyl chloride or oxalyl chloride) in an inert organic solvent (as hereinbefore described) or without a solvent at from -20°C the reflux temperature of the solvent, and then by reacting the acid halide obtained with an amine of the general formula (II) in the presence or absence of a tertiary amine (as hereinbefore described) in an inert organic solvent (as hereinbefore described), at a temperature of from 0°C to 40°C and (C) the method using a condensing agent such as DCC may be carried out, for example, by reacting a carboxylic acid of the general formula (VI) with an amine of the general formula (II) using DCC in the presence or absence of a tertiary amine (as hereinbefore described), in an inert organic solvent (as hereinbefore described) or without a solvent, at a temperature of from 0°C to 40°C. The reaction (A), (B) and (C) hereinbefore described are preferably carried out in an atmosphere of inert gas (e.g. argon or nitrogen) under anhydrous conditions. Reaction 2 may be carried out by reaction of the compound of formula IA with 2-mercaptoethylamine (HS-(CH₂)₂-NH₂) in an inert organic solvent (e.g. methylene chloride or acetonitrile), at a temperature of from ambient to 60°C. Reaction 3 may be carried out by reaction with anhydrous potassium carbonate or anhydrous sodium carbonate in an absolute alkanol (e.g. absolute methanol or absolute ethanol), generally at a temperature of from -10°C to 100°C. Reaction 4 may be carried out by using an aqueous solution of an alkali (e.g. potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate or sodium carbonate) in a water-miscible organic solvent (e.g. dimethoxyethane, THF (tetrahydrofuran), dioxan or a lower alkanol), generally at a temperature of from -10°C to 100°C. Reaction 5 is a hydrolysis under acidic conditions, and may be carried out by reaction with an aqueous solution of an organic acid (e.g. acetic acid, oxalic acid, p-toluenesulfonic acid or trifluoroacetic acid), or with an aqueous solution of an inorganic acid (e.g. hydrochloric acid or, sulfuric acid) in an inert organic solvent (e.g. methylene chloride, THF, dioxan or a lower alkanol, at a temperature of from ambient to the reflux temperature of a solvent. Reaction 6 may be carried out by reaction with anhydrous potassium carbonate or anhydrous sodium carbonate in an absolute alkanol corresponding to the desired group R 1′ (e.g. absolute methanol or absolute ethanol), generally at a temperature of from -10°C to 100°C. Reaction 7, when Z² is a substituted acyl group (the groups of (2)-(6) in those represented by Z), may be carried out by reaction with a halide or acid anhydride of the carboxylic acid corresponding to Z², in the presence of a tertiary amine (e.g. pyridine or triethylamine), in an inert organic solvent (e.g. methylene chloride, dimethylformamide, THF or ethyl acetate) or in the absence of a solvent, at a temperature of from 0°C to 50°C, or when Z² represents a group of the formula: (in which R¹⁰ is as hereinbefore defined), may be carried out by reaction with a halide of the compound corresponding to Z², in the presence of a base (e.g. a tertiary amine or a hydroxide or carbonate of an alkali metal), in an inert organic solvent (e.g. methylene chloride, dimethylformamide, THF or acetone) at a temperature of from 10°C to 50°C. Reaction 8 is a desilylation, and may be carried out by using tetrabutylammonium fluoride ( n Bu₄N⁺F⁻) in tetrahydrofuran at room temperature. Reaction 9 is an esterification, and may be carried out by reaction with a diazoalkane (e.g. diazomethane), in an inert organic solvent (e.g. diethyl ether, ethyl acetate, methylene chloride, acetone or a lower alkanol) at a temperature of from -10°C to 40°C, or by reaction with a lower alkanol in the presence of an acid (e.g. hydrochloric acid or p-toluenesulfonic acid) or in the presence of a condensing agent (e.g. dicyclohexylcarbodiimide), at a temperature of from -10°C to 50°C. Reaction 10 may be carried out by the same procedure as Reaction 7 when Z² represents a group of the formula: wherein R¹⁰ is as hereinbefore defined. The compounds of the general formulae (II), (III), (IV) and (V), used in the aforesaid schemes, may be prepared by the combination of known methods, for example, by using the series of reactions depicted in the following Scheme D, wherein Boc represents a tert-butoxycarbonyl group, cbz represents a benzyloxycarbonyl group and the other symbols are as hereinbefore defined. Each of the steps depicted in the foregoing scheme is well known to those skilled in the art. Throughout the specification, in each of the reactions, products may be purified by conventional methods, for example, distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate or washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions. Starting materials of the formula (VII) and (IX) and the reagents, used in the preparation of compounds of the present invention, are known compounds per se , or may be easily prepared by known methods. For example, the compounds of formula (VII), wherein m is 1 or 2, and of formula (IX), wherein m₁ is 1 or 2, are commercially available. The compounds of the general formula (I) and non-toxic salts thereof, of the present invention have an inhibitory effect on enkephalinase, and are, therefore, useful as analgesic, antianxiety or anticonvulsant agents, in mammals, especially humans. The inhibitory effect on enkephalinase and the analgic effect based on the inhibitory effect, of the compounds of the present invention were confirmed by the screening tests described below. Inhibitory effect on enkephalinase (1) Method Enkephalinase was obtained by the procedure as described in Journal of Neurochemistry, 39 , 1081 (1982). That is, to striata obtained from ddY male mice (weighing 28 ∼ 30 g), Tris hydrochloric acid buffer solution (referred to as "Tris buffer" hereafter) was added. The mixture was homogenised and centrifuged (1000 g × 5 minutes). The supernatant obtained was further centrifuged (20000 g × 1 minute ). The resulting pellet was washed with cold Tris buffer and resuspended in a fresh Tris buffer to use as an enzyme source of enkephalinase. The experiment was carried out according to the method described in Journal of Biological Chemistry, 255 , 2227 (1980). That is, the test compounds (10⁻⁵ ∼ 10⁻⁹ M) were dissolved in 2% DMSO/Tris buffer (50 µl). Incubation at 37°C for 60 minutes was started by adding thereto 150 µg of enzyme solution (×30 dilution of the above enzyme source) and 50 µl of a substrate solution containing succinyl-alanyl-alanyl-phenylalanyl (7-amido-4-methyl)coumarin (i.e. Suc-Ala-Ala-Phe-AMC, final concentration: 10⁻⁴ M) dissolved in 50 mM HEPES/NaOH buffer (pH 7.4). The reaction was stopped by the addition of thiorphan (10⁻⁶ M) and by heating the samples at 95°C for 15 minutes. In a second step, the incubation medium was further incubated at 56°C for 60 minutes in the presence of 0.75 µl of aminopeptidase M. The appearance of AMC fluorescence was measured (exc. 367 nm, em. 440 nm). Blank values were obtained by the same procedure as above described by using thiorphan (10⁻⁶ M) instead of the test compound. (2) Result The results are shown in Table I below. Inhibitory effect on bradykinin-induced biting-like response (1) Method The experiment was carried out according to the method described in Journal of Pharmacological Methods, 7 , 271 (1982). That is, male Sprague-Dawley rats (weighing 200 ∼ 300 g) were used. Implantation of a bradykinin (0.63 ∼ 1.25 µg in 0.5 ∼ 1.0 µl of distilled water) - filled cannula onto the tooth pulp and the fixation of it on the lower incisor surfaces were carried out under ethyl ether anesthesia. A micro-application of bradykinin onto the tooth pulp produced biting-like response and some other aversive behavior such as jumping, struggling, rubbing, scratching, escape, head-jerk and body-jerk within 1 minute. Only rats which showed a duration of 20 minutes or more for the biting-like responses before administration of the compound of the present invention, were used for further experiment. The test compounds suspended in 0.5 % carboxymethyl cellulose solution were administered either intraperitoneally or orally. After regular intervals bradykinin was administered. The number of rats which did not show the biting-like response after adminsitration (i.e. analgic state) was counted. (2) Result The results are shown in Table II below. The acute toxicity of the compounds of the present invention is very weak. For example, the acute toxicity (LD₅₀) of N-[3-(phthalid-3-yl)thio-2S-benzylpropionyl]-α-anilino-L-glutamic acid is 500-1000 mg/kg by intraperitoneal injection in mice. Therefore, the compounds of the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use. For the purpose above described, the compounds of the present invention will normally be administered systemically or partially, usually by oral or parenteral administration. The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person per dose are generally between 10 mg and 1 g, by oral administration, up to several times (preferably 1 to 4 times) per day, and between 1 mg and 100 mg, by parenteral administration (preferably, intravenous administration) up to several times (preferably 1 to 4 times) per day. As the doses to be used depend upon various factors there will be cases in which doses lower than or greater than the ranges specified above may be used. The present invention provides a pharmaceutical composition which comprises, as active ingredient, an amino acid derivative of general formula I or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or coating. Suitable compositions include solid compositions, liquid compositions and other compositions for oral administration and injections, external compositions and suppositories for parenteral administration. Solid compositions for oral administration, include compressed tablets, pills, capsules, dispersible powders, and granules. In such compositions, one or more of the active compounds are generally admixed with a least one inert diluent (e.g. lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium metasilicate aluminate). The compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents (e.g. magnsium stearate), disintegrating agents (e.g. cellulose calcium glycolate etc.), and agents to assist dissolution (glutamic acid, aspartic acid etc.) and stabilizing agent (e.g. lactose). The tablets or pills may, if desired, be coated with a film of gastric or enteric material (e.g. sugar, gelatin, hydroxypropylcellulose, hydroxypropylmethyl cellulose phthalate). Capsules include soft ones and hard ones. Liquid compositions for oral administration include pharmaceutically-acceptable solutions, emulsions, suspensions, syrups and elixirs. In such liquid compositions, one or more of the active compounds are admixed with inert diluents commonly used in the art (e.g. purified water, ethanol). Besides inert diluents, such compositions may also comprise adjuvants such as wetting agents and suspending agents, sweetening agents, flavouring agents, perfuming agents and preserving agents. Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compounds. Spray compositions may comprise additional substances other than inert diluents, e.g. stabilizing agents (e.g. sodium sulfite), isotonic buffer comprising (e.g. sodium chloride, sodium citrate, citric acid). For the preparation of such spray compositions, for example, the method described in the United States Patent No. 2868691 or 3095355 may be used. Injectable compositions for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such injectable compositions, one or more of the active compounds are admixed with at least one inert aqueous diluent (e.g. distilled water for injection or physiological salt solution) or inert non-aqueous diluent (e.g. propylene glycol, polyethylene glycol, olive oil, ethanol or POLYSORBATE 80 (registered trade mark). Injectable compositions may also comprise additional ingredients other than inert diluents, e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (e.g. lactose), assisting agents such as assisting agents for dissolution (e.g. glutamic acid or aspartic acid). They may be sterilized by filtration (through a bacteris-retaining filter), incorporation of sterilizing agents in the composition or irradiation. After sterilizing, they can also be converted into sterile solid compositions, for example, by freeze-drying, and thereafter dissolved in sterile water or some other sterile diluents for injection immediately before use. Other compositions for parenteral administration include liquids for external use, and endermic liniments (e.g. ointment), suppositories and pessaries which comprise one or more of the active compounds and may be prepared by known methods. The following Reference Examples and Examples illustrate the present invention. The solvents in parentheses show the eluting or developing solvents and the ratios of the solvents used are by volumn in chromatographic separations. Unless otherwise specified. "IR" was measured by KBr method and "NMR" was measured in deuterochloroform (CDCl₃) solution. Reference Example 1 N-(tert-butoxycarbonyl)-α-anilino-L-glutamic acid γ-benzyl ester To a solution of N-(tert-butoxycarbonyl)-L-glutamic acid γ-benzyl ester dicyclohexylamine salt (commercially available 5.18g) in methylene chloride (30 ml) was added pivaloyl chloride (1.35 ml) under cooling with ice, and the mixture was stirred for 10 minutes at room temperature. The reaction mixture was again cooled with ice, and then a solution of aniline (1 ml) in triethylamine (1.4 ml) was added dropwise thereto, and the mixture was stirred for 20 minutes at room temperature. The reaction mixture was diluted with ethyl acetate, washed with 1N hydrochloric acid, 1N aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium chloride, successively, dried over magnesium sulfate, and concentrated under reduced pressure. The residue (solid) was washed with n-hexane to give the title compound (2.9 g) having the following physical data: TLC (ethyl acetate : n-hexane = 1:1):Rf 0.74; NMR: δ 8.40 (1H, brs), 7.55 ∼ 6.90 (10H, m), 5.35 (1H, brd), 5.10 (2H, s), 4.40 ∼ 4.10 (1H, m), 2.80 ∼ 2.40 (2H, m), 2.40 ∼ 1.70 (2H, m), 1.42 (9H, s); MS:m/z 412(M⁺), 356, 339, 292. Reference Example 2 α-anilino-L-glutamic acid γ-benzyl ester trifluoroacetic acid salt To a solution of glutamic acid protected by a Boc group (2.9g, prepared in Reference Example 1) in methylene chloride (2 ml) was added trifluoroacetic acid (5.4 ml) under cooling with ice, and the mixture was stirred for 2.5 hours at room temperature. The reaction mixture was concentrated under reduced pressure to give the crude title compound (3.00 g) having the following physical data: TLC (ethyl acetate) : Rf 0.23; NMR: δ 9.50(1H, brs), 7.60 ∼ 6.80(10H, m), 5.00(2H, s), 4.60 ∼ 4.30(1H, m), 2.70 ∼ 2.50(2H, m), 2.50 ∼ 1.90(2H, m); MS:m/z 312, 204, 193, 192. Reference Example 3 N-(3-acetylthio-2RS-benzylpropionyl)-α-anilino-L-glutamic acid γ-benzyl ester To a solution of 3-acetylthio-2RS-benzylpropionic acid (prepared by the method described hereafter, 833 mg) in methylene chloride (1 ml) was added an excess amount of oxalyl chloride at room temperature, and the mixture was stirred for 30 minutes. Oxalyl chloride was fully distilled off from the reaction mixture, and to the residue was added methylene chloride (2 ml) to obtain a solution of acid chloride. To a solution of trifluoroacetic acid salt of the amine compound (prepared in Reference Example 2, 1.64 g) in a mixture of pyridine (2.83 ml) and methylene chloride (16 ml), was added dropwise the solution of acid chloride prepared hereinbefore under cooling with ice and the mixture was stirred for 15 minutes at room temperature. The reaction mixture was poured into water, washed with 1N hydrochloric acid, 1N aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium chloride, successively, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methyene chloride : n-hexane = 2 : 1 → methylene chloride → methylene chloride : methanol = 20 : 1) and further recrystallized from a mixture of ethyl acetate and n-hexane to give the title compound (743 mg) as a white powder having the following physical data: TLC (ethyl acetate : n-hexane = 1 : 1) : Rf 0.48; NMR: δ 8.52 and 8.38(1H, brs), 7.34 ∼ 7.00(15H, m), 6.44 ∼ 6.24(1H, m), 5.12 and 5.10(2H, s), 4.60 ∼ 4.30(1H, m), 3.24 ∼ 3.00 and 3.00 ∼ 2.82(4H, m), 2.76 ∼ 2.34(3H, m), 2.28 and 2.22(3H, s), 2.20 ∼ 1.82(2H, m); MS:m/z 532(M⁺), 489, 440, 370. 3-Acetylthio-2RS-benzylpropionic acid, used as a starting material in a procedure hereinbefore described, was prepared as follows. To 2RS-benzylacrylic acid (being on the market, 25 g) was added thioacetic acid (16 ml) and the mixture was refluxed for one hour by heating in an oil bath. An excess amount of thioacetic acid was distilled off from the residue and further distilled off as an azeotropic mixture with toluene. The residue was purified by column chromatography on silica gel (ethyl acetate : n-hexane : acetic acid = 5 : 95 : 0.05 → 20 : 80 : 0.05) to give 3-acetylthio-2RS-benzylpropionic acid (16.7 g) as colorless oil having the following physical data: TLC (n-hexane : ethyl acetate = 1 : 1) : Rf 0.3; MMR: δ 7.35 ∼ 7.14(5H, m), 3.2 ∼ 2.8(5H, m), 2.33(3H, s) ; MS:m/z 238(M⁺), 220. Example 1 N-(3-mercapto-2RS-benzylpropionyl)-α-anilino-L-glutamic acid and their γ-sodium salt Under an atmosphere of argon, to a solution of the benzyl ester compound (prepared in Reference Example 3, 743 mg) in a mixture of tetrahydrofuran (9 ml) and dimethoxyethane (1.4 ml) was added a solution of lithium hydroxide monohydrate (293 mg) in water (5 ml) at room temperature and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 1N hydrochloric acid under cooling with ice to acidify and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform → acetic acid : chloroform = 1 : 99) to give the title compound (387 mg as free acid) as a white powder having the following physical data: Melting point: 158.5 ∼ 160.0 °C; TLC (acetic acid : chloroform = 5 : 95) : Rf 0.20; NMR(CDCl₃ + DMSO-d₆ ) : δ 9.04 ∼ 8.86(1H, d like m)), 7.56 ∼ 7.40(2H, m), 7.36 ∼ 6.92(9H, m), 4.72 ∼ 4.46(1H, m), 3.02 ∼ 2.40 (6H, m), 2.40 ∼ 1.68(4H, m), 1.54(1H, t) ; MS:m/z 400(M⁺), 382, 366, 353, 335; IR: ν 3275, 1700, 1640, 1600, 1540, 1440, 1300, 1250, 750, 695 cm⁻¹. The free acid compound obtained above was dissolved in a small amount of methanol and 1N aqueous solution of sodium hydroxide and water were added thereto and the mixture was stirred for 5 minutes at room temperature. The reaction mixture was lyophilized to give the title compound ( as sodium salt) having the following physical data: TLC (chloroform : acetic acid = 95 : 5) : Rf 0.20; NMR(CD₃OD): δ 7.60 ∼ 7.00(10H, m)), 4.50 ∼ 4.20(1H, m), 3.05 ∼ 1.70(9H, m); IR: ν 3680 ∼ 2500(3270) 1635, 1595, 1540, 1440, 1400, 1310, 1250, 750, 695 cm⁻¹. The desired compounds shown in the following Table III were obtained by the same procedure as a series of reaction of Reference Example 1 → Reference Example 2 → Reference Example 3 → Example 1, by using a corresponding 3-acetylthio-2-substituted propionic acid. Example 2 The desired compounds shown in the following Table IV were obtained by the same procedure as a series of reactions of Reference Example 1 → Reference Example 2 (hydrochloric acid instead of trifluoroacetic acid was used) → Reference Example 3 → Example 1, by using corresponding starting material and the amine compound. Example 3 The desired compounds shown in the following Table V and VI were obtained by the same procedure as a series of reactions of Reference Example 1 (the amido bond-forming reaction using dicyclohexylcarbodiimide (DCC) as a condensing agent, was used instead of the method using a mixed acid anhydride with pivaloyl chloride) → Reference Example 2 (hydrochloric acid instead of trifluoroacetic acid was used) → Reference Example 3 → Example 1, by using corresponding starting material and the amine compound. Example 4 N-(3-mercapto-2RS-benzylpropionyl)-L-aspartic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide β-methyl ester To a solution of N-(3-acetylthio-2RS-benzylpropionyl)-L-aspartic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl) amide β-benzyl ester (prepared by the same procedure as a series of reactions of Reference Example 1 → Reference Example 2 → Reference Example 3, by using the corresponding starting materials, 1,686 g) in methanol (10 ml) was added potassium carbonate (0.688 g), and the mixture was stirred for one hour at room temperature. The reaction mixture was diluted with methylene chloride (100 ml), washed with water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride : methanol = 30 : 1) to give the title compound (0.735 g) as orange amorphous having the following physical data: TLC (methylene chloride : methanol = 95 : 5) : Rf 0.37; NMR: δ 8.32 and 7.98(1H, s), 7.68 ∼ 6.64(14H, m), 4.90 ∼ 4.75(1H, m), 3.88 ∼ 3.40(7H, m), 3.20 ∼ 1.92(10H, m), 1.40(1H, 2xt); MS:m/z 558(M⁺), 526, 510, 498: IR: ν 3600 ∼ 2500, 1715, 1650, 1610, 1490, 1290, 1180, 690. The following desired compound was obtained by the same procedure as above. (1) N-(3-mercapto-2RS-benzylpropionyl)-L-glutamic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide γ-methyl ester TLC (methanol : methylene chloride = 1 : 9) : Rf 0.56; NMR: δ 8.48 and 8.27(1H, s, 5 : 6), 7.70 ∼ 6.90(13H, m), 6.70 and 6.52(1H, d), 4.55 ∼ 4.28(1H, m), 3.80 ∼ 3.50(4H, m), 3.63 and 3.65(3H, s), 3.00 ∼ 1.84(9H, m), 2.80 and 2.76(3H, s), 1.44 and 1.39(1H, t); MS:m/z 572(M⁺), 540, 512; IR: ν 3300, 1740, 1650, 1500. Example 5 N-(3-mercapto-2RS-benzylpropionyl)-L-glutamic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide The title compound having the following physical data was obtained by the same procedure as Example 1, by using the methyl ester prepared in Example 4(1). TLC (methanol : benzene = 2 : 8) : Rf 0.2 ; Melting point : 126.0 ∼ 131.0 °C Reference Example 4 α-anilino-L-glutamic acid γ-tert-butyl ester Under an atmosphere of hydrogen, a mixture of N-(benzyloxycarbonyl)-α-anilino-L-glutamic acid γ-tert-butyl ester (7.80 g, prepared by the same procedure as Reference Example 1 (the amido bond forming reaction using DCC as a condensing agent, was used instead of the method using a mixed acid anhydride) by using N-(benzyloxycarbonyl)-L-glutamic acid γ-tert-butyl ester as starting material), palladium-carbon (10% ; 880 mg) and ethyl acetate (130 ml) was stirred for 3 hours at room temeperature. The reaction mixture was filtered, and to the filtrate was added ethyl acetate (20 ml) containing 4N hydrogen chloride, and then the mixture was concentrated under reduced pressure to give hydrochloric acid salt of the title compound as crude product. Example 6 N-(3-benzoylthio-2S-benzylpropionyl)-α-anilino-L-glutamic acid γ-tert-butyl ester The title compound having the following physical data was obtained by the same procedure as Reference Example 3, by using the amine compound prepared in Reference Example 4 and 3-benzoylthio-2S-benzylpropionic acid. TLC (n-hexane : ethyl acetate = 1 : 1) : Rf 0.56. Example 7 N-(3-mercapto-2S-benzylpropionyl)-α-anilino-L-glutamic acid γ-tert-butyl ester The title compound having the following physical data was obtained by the same procedure as Example 4, by using the benzoyl compound prepared in Example 6 TLC (n-hexane : ethyl acetate = 1 : 1) : Rf 0.53. Example 8 N-(3-mercapto-2S-benzylpropionyl)-α-anilino-L-glutamic acid To a solution of the tert-butyl ester (770 mg) prepared in Example 7, in ethyl acetate (3 ml) was added ethyl acetate (2 ml) containing 4N hydrogen chloride, and the mixture was stirred for two hours at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (methylene chloride : ethyl acetate = 9 : 1 → 4 : 1 → 2 : 1 → ethyl acetate) to give the title compound (300 mg) having the following physical data: TLC (chloroform : tetrahydrofuran : acetic acid = 15 : 4 : 1) : Rf 0.39; Optical rotation (c = 0.895, absolute C₂H₂OH) : [α] D -22.2°. The desired compounds shown in the following Table VII were obtained by the same procedure as a series of reaction of Reference Example 4 → Example 6 → Example 7 → Example 8, by using corresponding starting materials. Reference Example 5 N-(3-acetylthio-2RS-benzylpropionyl)-γ-anilino-L-glutamic acid α-tert-butyl ester The title compound having the following physical data was obtained by the same procedure as a series of reactions of Reference Example 1 → Reference Example 4 → Reference Example 3, by using N-(benzyloxycarbonyl)-L-glutamic acid α-tert-butyl ester as starting material. TLC (ethyl acetate : n-hexane = 1 : 1) : Rf 0.42. Reference Example 6 N-(3-acetylthio-2RS-benzylpropionyl)-γ-anilino-L-glutamic acid The title compound having the following physical data was obtained by the same procedure as Reference Example 2, by using the tert-butyl ester prepared in Reference Example 5 as starting material. TLC (ethyl acetate : methanol = 9 : 1) : Rf 0.12. Reference Example 7 N-(3-mercapto-2RS-benzylpropionyl)-α-anilino-L-glutamic acid γ-tert-butyl-diphenylsilyl ester To a solution of the carboxylic acid (1.69 g, prepared in Example 1) in dimethylformamide (12 ml) were added imidazole (0.631 g) and successively tert-butyldiphenylsilyl chloride (1.23 ml) at room temperature, and the mixture was stirred for 3 hours at the same temperature. The reaction mixture was dissolved in ether (150 ml), washed with 1N hydrochloric acid, 1N aqueous solution of sodium hydroxide and water, successively, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate: methylene chloride = 5 : 95 → 1 : 9) to give the title compound (2.37 g) as a white powder having the following physical data: TLC (ethyl acetate : methylene chloride : 1 : 9) : Rf 0.48 ; NMR: δ 8.58 and 8.46(1H, s × 2), 7.85 ∼ 6.98(20H, m), 6.84 ∼ 6.62(1H, d × 2), 4.56 ∼ 4.39(1H, m), 2.98 ∼ 1.02(19H, m); MS:m/z 638(M⁺), 581. Reference Example 8 N-(3-nicotinoylthio-2RS-benzylpropionyl)-α-anilino-L-glutamic acid γ-tert-butyl-diphenylsilyl ester To a mixture of the mercapto compound (1.43 g, prepared in Reference Example 7), nicotinic acid (0.276 g) and diphenylphosphoryl azide (0.99 ml) and dimethylformamide (5 ml), was added triethylamine (0.63 ml) at 0°C and the mixture was stirred for 3 hours at room temperature. To the reaction mixture was added water (30 ml) and the mixture was extracted with ethyl acetate (80 ml × 2). The extract was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride : ethyl acetate = 3 : 1 → 2 : 1) to give the title compound (0.35 g) as a white powder having the following physical data: TLC (methylene chloride : ethyl acetate = 2 : 1) : Rf 0.44 and 0.38; NMR: δ 9.12 and 9.02(1H, dd × 2), 8.73 and 8.70 (1H, dd × 2), 8.53 and 8.45(1H, s × 2), 8.13 and 7.95(1H, ddd × 2), 7.75 ∼ 7.00(21H, m), 6.60 ∼ 6.42(1H, d × 2), 4.52 ∼ 4.37(1H, m), 3.45 ∼ 1.50(9H, m), 1.11 ∼ 1.08(9H, s × 2) ; MS:m/z 685, 547. Example 9 N-(3-nicotinoylthio-2RS-benzylpropionyl)-α-anilino-L-glutamic acid A solution of the ester compound (350 mg, prepared in Reference Example 8) in a mixture of acetic acid (3 ml), tetrahydrofuran (1 ml) and water (1 ml) was stirred for 16 hours at room temperature, and the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform : methanol : acetic acid = 80 : 3 : 1 → 50 : 3 : 1) to give the title compound (175 mg) as a white powder having the following physical data: TLC (chloroform : methanol : acetic acid = 50 : 3 : 1) : Rf 0.47; NMR(CDCl₃ + DMSO - d₆ ) : δ 9.68 and 9.62(1H, s × 2), 9.05 and 9.00 (1H, d × 2), 8.77 and 8.73(1H, dd × 2), 8.34 ∼ 8.04(2H, m), 7.60 ∼ 6.96(11H, m), 4.62 ∼ 4.36(1H, m), 3.80 ∼1.60(9H, m); MS:m/z 487, 348, 335; IR: ν 3600 ∼ 2100 (3370, 3040, 2925), 1705, 1640, 1635, 1590, 1525, 1440, 1210, 915, 690 cm⁻¹. The desired compounds shown in the following Table IX and X were obtained by the same procedure as a series of reactions of Reference Example 7 → Reference Example 8 → Example 9, by using corresponding starting materials. Example 10 N-(3-nicotinoylthio-2S-benzylpropionyl)-α-anilino-L-aspartic acid hydrochloride The title compound having the following physical data was obtained by the same procedure as a series of reactions of Reference Example 1 (the amido bond forming reaction using DCC as a condensing agent, was used instead of the method using a mixed acid anhydride) → Reference Example 4 → Example 6 → Example 7 → Reference Example 8 → Example 8, by using N-(benzyloxycarbonyl)-L-aspartic acid β-tert-butyl ester dicyclohexylamine salt as starting material. TLC (methylene chloride : tetrahydrofuran : acetic acid = 7 : 2 : 1) : Rf 0.56 ; Optical rotation (c = 1.00, CH₃OH) : [α] D - 66.22°. Example 11 N-(3-benzoylthio-2S-benzylpropionyl)-α-anilino-L-aspartic acid The title compound having the following physical data was obtained by the same procedure as a series of reactions of Reference Example 1 (the amido bond forming reaction using DCC as a condensing agent, was used instead of the method using a mixed acid anhydride) → Reference Example 4 → Example 6 → Reference Example 6, by using N-(benzyloxycarbonyl)-L-aspartic acid β-tert-butyl ester dicyclohexylamine salt as starting material. TLC (chloroform : acetic acid = 95 : 5) : Rf 0.31; IR : ν 3290, 3040, 1700, 1645, 1600, 1520, 1440, 1200, 1170, 910, 755, 690 cm⁻¹. The following desired compound was obtained by the same procedure as above. (1) N-(3-benzoylthio-2S-benzylpropionyl)-α-anilino-L-glutamic acid TLC (chloroform : acetic acid = 95 : 5) : Rf 0.29; IR : ν 3270, 3050, 1705, 1655, 1640, 1600, 1530, 1490, 1445, 1205, 910, 750, 685 cm⁻¹. Reference Example 9 N-[3-(phthalid-3-yl)thio-2S-benzylpropionyl]-α-anilino-L-glutamic acid γ-tert-butyldiphenylsilyl ester To a solution of the thioether compound (178 mg, prepared by the same procedure as Reference Example 7 by using the compound prepared in Example 8 as starting material) in acetone (2 ml) were added 3-phthalidyl chloride (56.1 mg) and potassium carbonate (46 mg) at room temperature, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was diluted with a mixture of ethyl acetate and ether, washed with water and a saturated aqueous solution of sodium chloride, successively, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate: n-hexane = 1 : 2) to give the title compound (153.6 mg) having the following physical data : TLC (ethyl acetate : n-hexane = 1 : 2 ) : Rf 0.2. Example 12 N-[3-(phthalid-3-yl)thio-2S-benzylpropionyl]-α-anilino-L-glutamic acid The title compound having the following physical data was obtained by the same procedure as Example 9, by using the silyl ester prepared in Reference Example 9 as starting material. TLC (chloroform : acetic acid = 95 : 5) : Rf 0.40; IR : ν 3255, 1750, 1640, 1600, 1520, 1440 cm⁻¹. The following desired compounds were obtained by the same procedure as above. (1) N-[3-(phthalid-3-yl)thio-2S-benzylpropionyl]-α-anilino-L-aspartic acid TLC (chloroform : tetrahydrofuran : acetic acid = 15 : 4 : 1) : Rf 0.51; IR : ν 3280, 3030, 1760, 1640, 1600, 1525, 1440, 1285, 1170, 940, 760, 725, 695 cm⁻¹. (2) N-[3-(phthalid-3-yl)thio-2S-benzylpropionyl]-L-glutamic acid α-(2-benzthiazolyl)amide TLC (chloroform : acetic acid = 98 : 2) : Rf 0.25; IR : ν 3300, 1760, 1640, 1600, 1540, 1440 cm⁻¹. Example 13 N-[3-(phthalid-3R(or-3S)-yl)thio-2S-benzylpropionyl]-α-anilino-L-glutamic acid (3R isomer: = ) (3S isomer: = ...... ) The diastereomer (i.e. 3RS-mixture, prepared in Example 12) was recrystallized twice from ethyl acetate to give the 3R-isomer having the following physical data. Further, mother liquor obtained in the separation of R-isomer, was concentrated under reduced pressure and the residue was dissolved in ethanol and recrystallized twice from ethanol to give the 3S-isomer having the following physical data. (1) 3R-isomer TLC (methylene chloride : methanol = 9 : 1) : Rf 0.14; IR : ν 3270, 3060, 1758, 1732, 1671, 1646, 1531, 1446, 1295, 1177, 960, 756, 697 cm⁻¹. (2) 3S-isomer Melting point: 174° ∼ 176°C; TLC (methylene chloride : methanol = 9 : 1) : Rf 0.12; IR : ν 3286, 3060, 1774, 1709, 1677, 1639, 1533, 1445, 1290, 953, 726, 701 cm⁻¹. Formulation Example The following components were admixed in conventional manner and punched out to obtain 100 tablets each containing 50 mg of active ingredient. ° N-(3-mercapto-2RS-benzylpropionyl)-α-anilino-L-glutamic acid 5.0 g ° Cellulose calcium glycolate (disintegrating agent) 0.2 g ° Magnesium stearate (lubricating agent) 0.1 g ° Microcrystalline cellulose 4.7 g

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE An amino acid derivative of the general formula: (wherein R¹ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R² represents a carbocyclic or heterocyclic ring, unsubstituted or substituted by 1 to 3 substituents R³, R³ represents independently; (1) a halogen atom, (2) a trihalomethyl group, (3) a hydroxy group, (4) an alkyl group of 1 to 15 carbon atoms, (5) an alkoxy group of 1 to 4 carbon atoms, (6) an alkylthio, alkylsulfinyl or alkylsulfonyl group, of 1 to 4 carbon atoms, (7) a group of the formula: in which R⁴ represents a hydrogen atom, a halogen atom, a trihalomethyl group, a hydroxy group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms (8) a group of the formula: ―NR⁵R⁶ in which R⁵ and R⁶ independently represent a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (9) a group of the formula: ―CO―R⁷ in which R⁷ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R⁴ (in which R⁴ is as hereinbefore defined), (10) a group of the formula: ―COOR⁸ in which R⁸ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (11) a group of the formula: ―CONR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (12) a group of the formula: ―SO₂NR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (13) a cyano group, (14) a nitro group, or (15) a group of the formula: ―NHCO―R⁷, in which R⁷ is as hereinbefore defined, Z represents: (1) a hydrogen atom, (2) a group of the formula: ―COR⁹ in which R⁹ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, (3) a group of the formula: in which R¹⁰ is as hereinbefore defined, (4) a group of the formula: in which R¹¹ and R¹² independently represent a hydrogen atom, an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ is as hereinbefore defined, or R¹¹ and R¹² together represent an alkylene group of 4 or 5 carbon atoms and p is an integer of 1 or 2, (5) a group of the formula: in which the two R¹⁰ groups are independently as hereinbefore defined, (6) a group of the formula: in which R¹⁰ is as hereinbefore defined and g is an integer of 1 to 4, (7) a group of the formula: in which R¹⁰ is as hereinbefore defined, A represents a phenyl group or cycloalkyl group of 4 to 7 carbon atoms, each of which is substituted by R¹³, in which R¹³ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, and m is an integer of 1 to 4), or a non-toxic salt thereof. A compound according to claim 1, wherein Z represents a hydrogen atom. A compound according to claim 2, wherein R² represents a carbocyclic ring unsubstituted or substituted by R³. A compound according to claim 3, wherein the carbocyclic ring is a benzene or naphthalene ring. A compound according to claim 3, which is: N-(3-mercapto-2-benzylpropionyl)-α-anilinoaspartic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methoxyanilino)aspartic acid, N-(3-mercapto-2-benzylpropionyl)-α-anilinoglutamic acid, N-(3-mercapto-2-cyclohexylmethylpropionyl)-α-anilinoglutamic acid, N-[3-mercapto-2-(4-methoxybenzyl)propionyl]-α-anilinoglutamic acid, N-[3-mercapto-2-(4-methylbenzyl)propionyl]-α-anilinoglutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-fluoroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-chloroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(2-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(3-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methoxyanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-[4-(N,N-dimethylamino)anilino]glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-trifluoromethylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-decylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-cyanoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-carboxyanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-acetylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-nitroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-carbamoylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-sulfamoylanilino)glutamic acid or N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(1-naphthyl)amide, a β-methyl ester of a corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of a corresponding aspartic acid derivative, a γ-methyl ester of a corresponding glutamic acid derivative, or a non-toxic γ-carboxylate salt of a corresponding glutamic acid derivative. A compound according to claim 2, wherein R² represents a heterocyclic ring unsubstituted or substituted by R³. A compound according to claim 6, wherein the heterocyclic ring represented by R² is monocyclic or bicyclic incorporating a benzene ring, and contains one or two nitrogen or sulfur atoms. A compound according to claim 7, wherein the heterocyclic ring represented by R² is furan, thiophene, pyridine, pyrimidine, pyrazine, benzimidazole, benzthiazole, benzoxazole or benzodiazepine. A compound according to claim 6, which is: N-(3-mercapto-2-benzylpropionyl)aspartic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(4-pyridyl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(5-chloropyridin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(pyrazin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(pyrimidin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(2-benzthiazolyl)amide, or N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide, a β-methyl ester of a corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of a corresponding aspartic acid derivative, a γ-methyl ester of a corresponding glutamic acid derivative or a non-toxic γ-carboxylate salt of a corresponding glutamic acid derivative. A compound according to claim 1, wherein Z is other than hydrogen. A compound according to claim 10, which is: N-(3-benzoylthio-2-benzylpropionyl)-α-anilino glutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)-α-anilino glutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)glutamic acid α-(2-benzthiazolyl) amide, N-(3-diphenylacetylthio-2-benzylpropionyl)-α-anilinoglutamic acid, N-(3-isonicotinoylthio-2-benzylpropionyl)-α-anilinoglutamic acid, N-[3-(2,2-dimethyl-1,3-dioxolan-4-carbonyl)thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-[3-[N-(9-fluorenyl)succinamoyl]thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)-α-anilinoaspartic acid, N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]glutamic acid α-(2-benzthiazolyl)amide or N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]-α-anilinoaspartic acid, a β-methyl ester of the corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of the corresponding aspartic acid derivative, a γ-methyl ester of the corresponding glutamic acid derivative, or a non-toxic γ-carboxylate salt of the corresponding glutamic acid derivative. A compound according to any one of the preceding claims in which the amino acid derivative has the L-configuration. A process for the preparation of an amino acid derivative of the general formula: (wherein the various symbols are as defined in claim 1), which comprises: (i) reacting to form an amide bond a compound of the general formula: (wherein t Bu represents a tert-butyl group and the other symbols are as defined in claim 1) with a compound of the general formula: (wherein Z¹ represents a group of the formula: -COR⁹ (in which R⁹ is as defined in claim 1) and A is as defined in claim 1); (ii) converting to a group -SH the group Z¹-S in a compound of the general formula: (wherein the various symbols are as defined in claim 1), or (wherein the various symbols are as defined in claim 1); (iii) hydrolyzing to convert to a group COOH the group COO t Bu in a compound of the general formula: (wherein the various symbols are as defined in claim 1), (wherein the various symbols are as defined in claim 1), or (wherein Z² represents the group other than a hydrogen atom in the groups represented by Z (Z is as hereinbefore defined) and the other symbols are as defined in claim 1) or to convert to a group COOH the group COOR¹⁴ in a compound of the general formula: (wherein R¹⁴ represents a silyl group substituted by three substituents which are selected from an alkyl group of 1 to 4 carbon atoms and a phenyl group, and the other symbols are as defined in claim 1) under acidic conditions, (iv) hydrolyzing under alkaline conditions to convert to a group SH the group Z¹S and to convert to a group COOH the groups COOBn for COOR 1' in a compound of the general formula: (wherein Bn represents a benzyl group and m₁ is an integer of 2 to 4, and the other symbols are as defined in claim 1), (wherein the various symbols are as defined in claim 1), or (wherein R 1' is as hereinbefore defined and the other symbols are as defined in claim 1), (v) converting to a group SH the group Z¹S- of a compound of the general formula: (wherein the various symbols are as defined in claim 1); (vi) converting to a group COOR 1' (in which R 1' represents an alkyl group containing 1 to 4 carbon atoms) the group COOBn of a compound of the general formula: (wherein the various symbols are as defined in claim 1), or (wherein the various symbols are as defined in claim 1), and converting to a group -SH the group Z¹S in the compound of the general formula (III); (vii) converting to a group Z²S (in which Z² represents a group within the definition of Z as defined in claim 1 with the exception of hydrogen) the SH group in a compound of the general formula: (wherein the various symbols are as defined in claim 1); (viii) desilylating a compound of the general formula: (wherein the various symbols are as defined in claim 1) to convert the group COOR¹⁴ to COOH; (ix) esterifying a compound of the general formula: (wherein the various symbols are as defined in claim 1) to convert the group COOH to a group COOR 1' in which R 1' is as hereinbefore defined; or (x) reacting a compound of the general formula: (wherein the various symbols are as defined in claim 1) with a halide of the group of the general formula: (wherein R¹⁰ is as defined in claim 1), and optionally converting an amino acid derivative of general formula (I) thus obtained into a non-toxic salt thereof. A pharmaceutical composition which comprises, as active ingredient, an amino acid derivative of the general formula: (wherein the various symbols are as defined in claim 1) or a non-toxic salt thereof in association with a pharmaceutically acceptable carrier or coating. An amino acid derivative of the general formula: (wherein the various symbols are as defined in claim 1) or a non-toxic salt thereof, for use as an analgesic, antianxiety or anticonvulsant agent. Claims for the following Contracting States : ES, GR A process for the preparation of an amino acid derivative of the general formula: (wherein R¹ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R² represents a carbocyclic or heterocyclic ring, unsubstituted or substituted by 1 to 3 substituents R³, R³ represents independently; (1) a halogen atom, (2) a trihalomethyl group, (3) a hydroxy group, (4) an alkyl group of 1 to 15 carbon atoms, (5) an alkoxy group of 1 to 4 carbon atoms, (6) an alkylthio, alkylsulfinyl or alkylsulfonyl group, of 1 to 4 carbon atoms, (7) a group of the formula: in which R⁴ represents a hydrogen atom, a halogen atom, a trihalomethyl group, a hydroxy group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms (8) a group of the formula: ―NR⁵R⁶ in which R⁵ and R⁶ independently represent a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (9) a group of the formula: ―CO―R⁷ in which R⁷ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R⁴ (in which R⁴ is as hereinbefore defined), (10) a group of the formula: ―COOR⁸ in which R⁸ represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, (11) a group of the formula: ―CONR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (12) a group of the formula: ―SO₂NR⁵R⁶ in which R⁵ and R⁶ are as hereinbefore defined, (13) a cyano group, (14) a nitro group, or (15) a group of the formula: ―NHCO―R⁷, in which R⁷ is as hereinbefore defined, Z represents: (1) a hydrogen atom, (2) a group of the formula: ―COR⁹ in which R⁹ represents an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, (3) a group of the formula: in which R¹⁰ is as hereinbefore defined, (4) a group of the formula: in which R¹¹ and R¹² independently represent a hydrogen atom, an alkyl group of 1 to 4 carbon atoms or a phenyl group substituted by R¹⁰, in which R¹⁰ is as hereinbefore defined, or R¹¹ and R¹² together represent an alkylene group of 4 or 5 carbon atoms and p is an integer of 1 or 2, (5) a group of the formula: in which the two R¹⁰ groups are independently as hereinbefore defined, (6) a group of the formula: in which R¹⁰ is as hereinbefore defined and q is an integer of 1 to 4, (7) a group of the formula: in which R¹⁰ is as hereinbefore defined, A represents a phenyl group or cycloalkyl group of 4 to 7 carbon atoms, each of which is substituted by R¹³, in which R¹³ represents a hydrogen atom, a halogen atom, a trihalomethyl group, an alkyl group of 1 to 4 carbon atoms or an alkoxy group of 1 to 4 carbon atoms, and m is an integer of 1 to 4), which process comprises: (i) reacting to form an amide bond a compound of the general formula: (wherein t Bu represents a tert-butyl group and the other symbols are as hereinbefore defined) with a compound of the general formula: (wherein Z¹ represents a group of the formula: -COR⁹ (in which R⁹ is as hereinbefore defined) and A is as hereinbefore defined); (ii) converting to a group -SH the group Z¹-S in a compound of the general formula: (wherein the various symbols are as hereinbefore defined), or (wherein the various symbols are as hereinbefore defined); (iii) hydrolyzing to convert to a group COOH the group COO t Bu in a compound of the general formula: (wherein the various symbols are as hereinbefore defined), (wherein the various symbols are as hereinbefore defined), or (wherein Z² represents the group other than a hydrogen atom in the groups represented by Z (Z is as hereinbefore defined) and the other symbols are as hereinbefore defined) or to convert to a group COOH the group COOR¹⁴ in a compound of the general formula: (wherein R¹⁴ represents a silyl group substituted by three substituents which are selected from an alkyl group of 1 to 4 carbon atoms and a phenyl group, and the other symbols are as hereinbefore defined) under acidic conditions, (iv) hydrolyzing under alkaline conditions to convert to a group SH the group Z¹S and to convert to a group COOH the groups COOBn or COOR 1' in a compound of the general formula: (wherein Bn represents a benzyl group and m₁ is an integer of 2 to 4, and the other symbols are as hereinbefore defined), (wherein the various symbols are as hereinbefore defined), or (wherein R 1' is as hereinbefore defined and the other symbols are as hereinbefore defined), (v) converting to a group SH the group Z¹S- of a compound of the general formula: (wherein the various symbols are as hereinbefore defined); (vi) converting to a group COOR 1' (in which R 1' represents an alkyl group containing 1 to 4 carbon atoms) the group COOBn of a compound of the general formula: (wherein the various symbols are as herebefore defined), or (wherein the various symbols are as hereinbefore defined), and converting to a group -SH the group Z¹S in the compound of the general formula (III); (vii) converting to a group Z²S (in which Z² represents a group within the definition of Z as hereinbefore defined with the exception of hydrogen) the SH group in a compound of the general formula: (wherein the various symbols are as hereinbefore defined); (viii) desilylating a compound of the general formula: (wherein the various symbols are as hereinbefore defined) to convert the group COOR¹⁴ to COOH; (ix) esterifying a compound of the general formula: (wherein the various symbols are as hereinbefore defined) to convert the group COOH to a group COOR 1' in which R 1' is as hereinbefore defined; or (x) reacting a compound of the general formula: (wherein the various symbols are as hereinbefore defined) with a halide of the group of the general formula: (wherein R¹⁰ is as hereinbefore defined); and optionally converting an amino acid derivative of general formula (I) thus obtained into a non-toxic salt thereof. A process according to claim 1, wherein Z represents a hydrogen atom. A process according to claim 2, wherein R² represents a carbocyclic ring unsubstituted or substituted by R³. A process according to claim 3, wherein the carbocyclic ring is a benzene or naphthalene ring. A process according to claim 3, for the preparation of a compound which is: N-(3-mercapto-2-benzylpropionyl)-α-anilinoaspartic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methoxyanilino)aspartic acid, N-(3-mercapto-2-benzylpropionyl)-α-anilinoglutamic acid, N-(3-mercapto-2-cyclohexylmethylpropionyl)-α-anilinoglutamic acid, N-[3-mercapto-2-(4-methoxybenzyl)propionyl]-α-anilinoglutamic acid, N-[3-mercapto-2-(4-methylbenzyl)propionyl]-α-anilinoglutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-fluoroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-chloroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(2-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(3-iodoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methoxyanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-[4-(N,N-dimethylamino)anilino]glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-trifluoromethylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-methylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-decylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-cyanoanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-carboxyanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-acetylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-nitroanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-carbamoylanilino)glutamic acid, N-(3-mercapto-2-benzylpropionyl)-α-(4-sulfamoylanilino)glutamic acid or N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(1-naphthyl)amide, a β-methyl ester of a corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of a corresponding aspartic acid derivative, a γ-methyl ester of a corresponding glutamic acid derivative, or a non-toxic γ-carboxylate salt of a corresponding glutamic acid derivative. A process according to claim 2, wherein R² represents a heterocyclic ring unsubstituted or substituted by R³. A process according to claim 6, wherein the heterocyclic ring represented by R² is monocyclic or bicyclic incorporating a benzene ring, and contains one or two nitrogen or sulfur atoms. A process according to claim 7, wherein the heterocyclic ring represented by R² is furan, thiophene, pyridine, pyrimidine, pyrazine, benzimidazole, benzthiazole, benzoxazole or benzodiazepine. A process according to claim 6, for the preparation of a compound which is: N-(3-mercapto-2-benzylpropionyl)aspartic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(4-pyridyl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(5-chloropyridin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(pyrazin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(pyrimidin-2-yl)amide, N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(2-benzthiazolyl)amide, or N-(3-mercapto-2-benzylpropionyl)glutamic acid α-(2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-7-yl)amide, a β-methyl ester of a corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of a corresponding aspartic acid derivative, a γ-methyl ester of a corresponding glutamic acid derivative or a non-toxic γ-carboxylate salt of a corresponding glutamic acid derivative. A process according to claim 1, wherein Z is other than hydrogen. A process according to claim 10, for the preparation of a compound which is: N-(3-benzoylthio-2-benzylpropionyl)-α-anilino glutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)-α-anilino glutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)glutamic acid α-(2-benzthiazolyl) amide, N-(3-diphenylacetylthio-2-benzylpropionyl)-α-anilinoglutamic acid, N-(3-isonicotinoylthio-2-benzylpropionyl)-α-anilinoglutamic acid, N-[3-(2,2-dimethyl-1,3-dioxolan-4-carbonyl)thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-[3-[N-(9-fluorenyl)succinamoyl]thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-(3-nicotinoylthio-2-benzylpropionyl)-α-anilinoaspartic acid, N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]-α-anilinoglutamic acid, N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]glutamic acid α-(2-benzthiazolyl)amide or N-[3-(phthalid-3-yl)thio-2-benzylpropionyl]-α-anilinoaspartic acid a β-methyl ester of the corresponding aspartic acid derivative, a non-toxic β-carboxylate salt of the corresponding aspartic acid derivative, a γ-methyl ester of the corresponding glutamic acid derivative, or a non-toxic γ-carboxylate salt of the corresponding glutamic acid derivative. A process according to any one of the preceding claims in which the amino acid derivative has the L-configuration.

Inventors: AISHITA HIDEKI ONO PHARMACEUTI, ARAI YOSHINOBU ONO PHARMACEUTI, KAWAMURA MASANORI ONO PHARMACE, AISHITA, HIDEKI ONO PHARMACEUTICAL CO. LTD., ARAI, YOSHINOBU ONO PHARMACEUTICAL CO. LTD., KAWAMURA, MASANORI ONO PHARMACEUTICAL CO. LTD.
Applicants: ONO PHARMACEUTICAL CO, ONO PHARMACEUTICAL CO., LTD.
Application year: 1989
Main classification: C07C323
IPC codes: C07C327, C07D213, A61K31, A61P43, C07D239, C07D417, A61P25, C07D243, C12N9, C07D277, C07D521, C07D317, C07C323, C07D307, C07D237, C07F7, C07D241